0AAX Stock Overview
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in the Netherlands and rest of Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IGEA Pharma N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.009 |
| 52 Week High | CHF0.21 |
| 52 Week Low | CHF0.009 |
| Beta | -0.29 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0AAX | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 2.5% |
| 1Y | n/a | -10.0% | 5.8% |
Return vs Industry: Insufficient data to determine how 0AAX performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how 0AAX performed against the UK Market.
Price Volatility
| 0AAX volatility | |
|---|---|
| 0AAX Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0AAX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0AAX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1 | Pierpaolo Cerani | www.igeapharma.nl |
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in the United States and the Netherlands. It offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand; and COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. The company also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices.
IGEA Pharma N.V. Fundamentals Summary
| 0AAX fundamental statistics | |
|---|---|
| Market cap | CHF1.69m |
| Earnings (TTM) | -CHF714.08k |
| Revenue (TTM) | CHF87.50k |
19.3x
P/S Ratio-2.4x
P/E RatioIs 0AAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0AAX income statement (TTM) | |
|---|---|
| Revenue | €90.80k |
| Cost of Revenue | €63.90k |
| Gross Profit | €26.90k |
| Other Expenses | €767.90k |
| Earnings | -€741.00k |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0022 |
| Gross Margin | 29.63% |
| Net Profit Margin | -816.08% |
| Debt/Equity Ratio | 11.0% |
How did 0AAX perform over the long term?
See historical performance and comparison